Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623138 | 0.98 | PDCD1 (0.39) | PDCD1CD274CHRNB2CHRNA4HTR2A | |
| SCHEMBL7110286 | 0.94 | PDCD1 (0.38) | PDCD1CD274CHRNB2CHRNA4HTR2A | |
| SCHEMBL6890691 | 0.94 | PDCD1 (0.38) | PDCD1CD274CHRNB2CHRNA4HTR2A | |
| SCHEMBL1453704 | 0.91 | PDCD1 (0.34) | PDCD1CD274CHRNB2CHRNA4HTR2A | |
| SCHEMBL1452035 | 0.90 | ALDH1A1 (0.40) | PDCD1CD274MAPK1 | |
| SCHEMBL28807858 | 0.89 | BCHE (0.36) | PDCD1CD274LMNAMAPK1 | |
| SCHEMBL27546243 | 0.89 | PDCD1 (0.35) | PDCD1CD274CHRNB2CHRNA4USP30 | |
| SCHEMBL5084813 | 0.89 | PDCD1 (0.39) | PDCD1CD274CHRNB2CHRNA4HTR2A | |
| SCHEMBL27489709 | 0.87 | SOAT1 (0.37) | — | |
| SCHEMBL3997096 | 0.86 | PDCD1 (0.35) | PDCD1CD274CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556417-B1 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | BASELL POLYOLEFINE GMBH (DE) | 2009-06-10 | — | — | EP | disclosed |
| EP-1554296-B1 | RACEMOSELECTIVE PREPARATION OF ISOLABLE ANSA-METALLOCENE BIPHENOXIDE COMPLEXES | BASELL POLYOLEFINE GMBH (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-7358381-B2 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | BASELL POLYOLEFINE GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| US-7193099-B2 | Racemoselective preparation of isolable ansa-metallocene biphenoxide complexes | BASELL POLYOLEFINE GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | EQUISTAR CHEMICALS, LP | 2006-05-25 | — | — | US | disclosed |
| US-20060052587-A1 | Racemoselective preparation of isolable ansa-metallocene biphenoxide complexes | BASELL POLYOLEFINE GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | ITPA, IMPA1, INTS9 | PDCD1 411/4885CD274 88/4885CHRNB2 3477/4885 |
| US-20060052587-A1 | Racemoselective preparation of isolable ansa-metallocene biphenoxide complexes | ITPA, NBAS, ARSA | PDCD1 762/4885CD274 482/4885CHRNB2 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.